Validated liquid chromatography-tandem mass spectroscopy method for the simultaneous quantification of four antimycotic agents in human serum

Therapeutic Drug Monitoring

Volumn 32, Issue 4, 2010, Pages 453-457

  Chahbouni, Abdel ^a   Wilhelm, Abraham J ^a   Den Burger, Jeroen C G ^a   Sinjewel, Arno ^a   Vos, René M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

antimycotics; fluconazole; itraconazole; posaconazole; voriconazole

Indexed keywords

FLUCONAZOLE; HYDROXYITRACONAZOLE; ITRACONAZOLE; KETOCONAZOLE; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; TRIAZOLE DERIVATIVE;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG STRUCTURE; ELECTROSPRAY; HUMAN; LIQUID CHROMATOGRAPHY; PRECIPITATION; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; BLOOD; CALIBRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; QUALITY CONTROL; REPRODUCIBILITY;

ANTIFUNGAL AGENTS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; INDICATORS AND REAGENTS; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; TRIAZOLES;

EID: 77955176612     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181e185fd     Document Type: Article

References (29)

1. Hope WW, Billaud EM, Lestner J, et al. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis. 2008;21:580-586.
2. Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit. 2008;30:167-172.
3. Glasmacher A, Prentice A, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol. 2003;21:4615-4626.
4. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201-211.
5. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44:2-12.
6. Lebeaux D, Lanternier F, Elie C, et al. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother. 2009;53:5224-5229.
7. Lestner JM, Roberts SA, Moore CB, et al. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis. 2009;49:928-930.
8. Imhof A, Schaer DJ, Schanz U, et al. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly. 2006;136:739-742.
9. Tan K, Brayshaw N, Tomaszewski K, et al. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol. 2006;46:235-243.
10. Alffenaar JW, de Vos T, Uges DR, et al. High voriconazole trough levels in relation to hepatic function: how to adjust the dosage? Br J Clin Pharmacol. 2009;67:262-263.
11. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53:24-34.
12. Bruggemann RJ, Donnelly JP, Aarnoutse RE, et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit. 2008;30:403-411.
13. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327-360.
14. Rogers TR, Frost S. Newer antifungal agents for invasive fungal infections in patients with haematological malignancy. Br J Haematol. 2009;144: 629-641.
15. Marr K, Boeckh M. Practice guidelines for fungal infections: a risk-guided approach. Clin Infect Dis. 2001;32:321.
16. Wirk B, Wingard JR. Combination antifungal therapy: from bench to bedside. Curr Infect Dis Rep. 2008;10:466-472.
17. Kousoulos C, Tsatsou G, Apostolou C, et al. Development of a high-throughput method for the determination of itraconazole and its hydroxy metabolite in human plasma, employing automated liquid-liquid extraction based on 96-well format plates and LC/MS/MS. Anal Bioanal Chem. 2006;384:199-207.
18. Vogeser M, Spohrer U, Schiel X. Determination of itraconazole and hydroxyitraconazole in plasma by use of liquid chromatography-tandem mass spectrometry with on-line solid-phase extraction. Clin Chem Lab Med. 2003;41:915-920.
19. Wu D, Wade KC, Paul DJ, et al. A rapid and sensitive LC-MS/MS method for determination of fluconazole in human plasma and its application in infants with Candida infections. Ther Drug Monit. 2009; 31:703-709.
20. Shen JX, Krishna G, Hayes RN. A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma. J Pharm Biomed Anal. 2007;43:228-236.
21. Zhou L, Glickman RD, Chen N, et al. Determination of voriconazole in aqueous humor by liquid chromatography-electrospray ionization-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;776: 213-220.
22. Chhun S, Rey E, Tran A, et al. Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;852:223-228.
23. Dadgar D, Burnett PE, Choc MG, et al. Application issues in bioanalytical method validation, sample analysis and data reporting. J Pharm Biomed Anal. 1995;13:89-97.
24. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation-a revisit with a decade of progress. Pharm Res. 2000;17:1551-1557.
25. Food and Drug Administration, Guidance for industry on bioanalytical method validation. Federal Register. 2001;66:28526.
26. Chambers E, Wagrowski-Diehl DM, Lu ZL, et al. Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;852: 22-34.
27. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem. 2003;75:3019-3030.
28. Matuszewski BK. Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;830:293-300.
29. Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002;46:2546-2553.